IVG CORP.Common Stock Issuance Agreement • October 10th, 2001 • Ivg Corp • Blank checks • Delaware
EX-10.18 4 filename4.htm CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Execution Version VIR...Common Stock Issuance Agreement • May 5th, 2020 • Delaware
THIS COMMON STOCK ISSUANCE AGREEMENT (the “Agreement”) is effective as of the 16th day of October, 2017 (the “Effective Date”), by and among VIR BIOTECHNOLOGY, INC., a Delaware corporation (the “Company”), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (“Purchaser” and, together with Company, the “Parties”). Capitalized terms used and not otherwise defined herein shall have the meaning ascribed thereto in the License Agreement (as defined below).
RECITALSCommon Stock Issuance Agreement • May 24th, 2002 • Zixit Corp • Services-computer programming, data processing, etc. • California
ContractCommon Stock Issuance Agreement • May 5th, 2020 • Delaware
EX-10.1 3 exhibit101commonstockagr.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version \\PH - 036137/000006 - 396952 v6 COMMON STOCK ISSUANCE AGREEMENT THIS COMMON STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of December 7, 2018, by and among Fibrocell Science, Inc., a Delaware corporation (the “Company”), and EB Research Partnership, Inc., a New York not-for-profit corporation (“EBRP”), and Epidermolysis Bullosa Medical Research Foundation, a California domestic non- profit corporation (“EBRF”) (each of EBRP and EBRF, a “Purchaser” and collectively, the “Purchasers”). For this and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 1. Issuance of Shares. On the date hereof, the Company shall issue and sell to each Purchaser, and each Purchaser shall purchase from the Company, such number of shares (the “Shares”) of the Company’s common stock, par value $0.0
AMENDMENT NO. 1 TO THE COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 1 to the Common Stock Issuance Agreement (“Amendment”) is made and entered into, effective as of December 17, 2019 (“Amendment Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are referred to in this Amendment as a “Party” and together, the “Parties”.
INTRINSIC MEDICINE, INC. COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • April 8th, 2022 • Intrinsic Medicine, Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK ISSUANCE AGREEMENT (this “Agreement”) is entered into as of the date signed by the last party to sign it (the “Effective Date”), by and between INTRINSIC MEDICINE, INC., a Delaware corporation (the “Company”), and SOSV IV LLC, a Delaware limited liability company (“Recipient” and together with the Company, a “party”).
QUANERGY SYSTEMS, INC. COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • April 4th, 2022 • Quanergy Systems, Inc. • Motor vehicle parts & accessories • New York
This COMMON STOCK ISSUANCE AGREEMENT (this “Agreement”) is made and entered into effective as of March 31, 2022 (the “Effective Date”), by and between QUANERGY SYSTEMS, INC., a Delaware corporation (f/k/a CITIC Capital Acquisition Corp., the “Company”), and CITIC CAPITAL ACQUISITION LLC, a Cayman Islands limited liability company (“CITIC”). Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Letter Agreement (as defined below).
AMPLIPHI BIOSCIENCES CORPORATION FIRST AMENDMENT TO COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • June 30th, 2017 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
This First Amendment to Common Stock Issuance Agreement (this “Amendment”) is made as of June 27, 2017, by and among AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), and the persons and entities listed on Exhibit A hereto (each, a “Holder” and collectively, the “Holders”). All capitalized terms used in this Amendment but not defined herein shall have their respective meanings as set forth in the Agreement.
EXECUTION Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omitted information. 1...Common Stock Issuance Agreement • January 20th, 2023 • Summit Therapeutics Inc. • Pharmaceutical preparations • New York
DISC MEDICINE, INC. COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • December 29th, 2022 • Disc Medicine, Inc. • Pharmaceutical preparations • Delaware
This Common Stock Issuance Agreement (this “Agreement”) is made as of December 29, 2022, by and between Disc Medicine, Inc., a Delaware corporation with an office and place of business at 321 Arsenal Street, Suite 101, Watertown, MA 02472 (the “Company”), F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche Financetogether referred to as “Roche”).
AMPLIPHI BIOSCIENCES CORPORATION COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • April 8th, 2016 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
This Common Stock Issuance Agreement (this “Agreement”) is made as of April 8, 2016, by and among AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), and the persons and entities listed on Exhibit A hereto (each, a “Holder” and collectively, the “Holders”).
QUANERGY SYSTEMS, INC. COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • April 4th, 2022 • Quanergy Systems, Inc. • Motor vehicle parts & accessories • New York
This COMMON STOCK ISSUANCE AGREEMENT (this “Agreement”) is made and entered into effective as of March 31, 2022 (the “Effective Date”), by and between QUANERGY SYSTEMS, INC., a Delaware corporation (f/k/a CITIC Capital Acquisition Corp., the “Company”), and RAYMOND JAMES & ASSOCIATES, INC., a Florida corporation (“Raymond James”). Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Letter Agreement (as defined below).
EXHIBIT BCommon Stock Issuance Agreement • April 5th, 2000 • Rosetta Inpharmatics Inc • Services-commercial physical & biological research • Washington
SETTLEMENT AGREEMENT AND RELEASE OF CLAIMSCommon Stock Issuance Agreement • June 19th, 2006 • Artes Medical Inc • Pharmaceutical preparations • California
THIS SETTLEMENT AGREEMENT AND RELEASE OF CLAIMS (the “Agreement”) is entered into by and between Artes Medical, Inc. (formerly, Artes Medical USA, Inc.), a Delaware corporation (“Artes Medical”), FormMed Biomedicals AG, a Swiss company subject to Swiss corporate law (“FormMed”), and Dr. Martin Lemperle, an individual and the sole shareholder of FormMed (“Lemperle”) (collectively referred to as the “Parties”) as of October 26, 2005 (the “Effective Date”).
